Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$247M |
| 2 |
Johnson & Johnson
JNJ
|
+$225M |
| 3 |
MON
Monsanto Co
MON
|
+$213M |
| 4 |
AET
Aetna Inc
AET
|
+$208M |
| 5 |
Broadcom
AVGO
|
+$176M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$227M |
| 2 |
Microsoft
MSFT
|
+$224M |
| 3 |
Alphabet (Google) Class C
GOOG
|
+$205M |
| 4 |
Nike
NKE
|
+$187M |
| 5 |
Pfizer
PFE
|
+$184M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 14.12% |
| 2 | Technology | 12.96% |
| 3 | Healthcare | 12.08% |
| 4 | Industrials | 11.23% |
| 5 | Consumer Staples | 8.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
426
Weis Markets
WMK
$1.77B
| $39.7M | 0.06% |
593,800
+4,400
| +0.7% | +$254K |
|
427
Medifast
MED
$128M
| $39.6M | 0.06% |
951,500
+4,300
| +0.5% | +$173K |
|
428
Xylem
XYL
$28.1B
| $39.6M | 0.06% |
+799,900
| New | +$40.6M |
|
429
Portland General Electric
POR
$5.92B
| $39.3M | 0.06% |
907,000
+247,400
| +38% | +$10.4M |
|
430
Vail Resorts
MTN
$5.18B
| $39.1M | 0.06% |
242,550
-52,950
| -18% | -$8.41M |
|
431
American States Water
AWR
$3.52B
| $39.1M | 0.06% |
858,300
+23,700
| +3% | +$988K |
|
432
AngloGold Ashanti
AU
$48.1B
| $39.1M | 0.06% |
3,718,600
-168,200
| -4% | -$2.04M |
|
|
SCG
433
DELISTED
Scana
SCG
| $39.1M | 0.06% |
533,000
+290,000
| +119% | +$20.7M |
|
434
Veeco
VECO
$3.28B
| $39M | 0.06% |
1,338,900
-99,500
| -7% | -$2.49M |
|
435
NETGEAR
NTGR
$647M
| $38.9M | 0.06% |
715,800
-23,800
| -3% | -$1.27M |
|
|
CIT
436
DELISTED
CIT Group Inc.
CIT
| $38.7M | 0.06% |
+907,300
| New | +$35.7M |
|
437
Equifax
EFX
$21.8B
| $38.7M | 0.06% |
327,395
+308,900
| +1,670% | +$37.8M |
|
|
DOOR
438
DELISTED
MASONITE INTERNATIONAL CORP
DOOR
| $38.7M | 0.06% |
587,400
-93,500
| -14% | -$5.86M |
|
|
WNS
439
DELISTED
WNS Holdings
WNS
| $38.5M | 0.06% |
1,398,800
+133,500
| +11% | +$3.6M |
|
440
Franklin Resources
BEN
$17.2B
| $38.5M | 0.06% |
+972,900
| New | +$36.4M |
|
|
AKS
441
DELISTED
AK Steel Holding Corp
AKS
| $38.3M | 0.06% |
3,750,800
+2,256,201
| +151% | +$17.2M |
|
442
AstraZeneca
AZN
$244B
| $38.1M | 0.06% |
697,400
-2,153,950
| -76% | -$122M |
|
443
TSMC
TSM
$2.23T
| $37.9M | 0.06% |
1,317,651
-1,104,800
| -46% | -$33.2M |
|
444
Radian Group
RDN
$4.92B
| $37.8M | 0.06% |
2,104,804
-351,096
| -14% | -$5.27M |
|
445
Carnival Corporation Ltd
CCL
$38.9B
| $37.6M | 0.06% |
+721,900
| New | +$36.1M |
|
446
Scotiabank
BNS
$111B
| $37.3M | 0.06% |
670,100
+122,000
| +22% | +$6.65M |
|
447
Coca-Cola Europacific Partners
CCEP
$47.5B
| $37.3M | 0.06% |
1,187,600
+956,100
| +413% | +$33.7M |
|
448
Cooper Companies
COO
$14.9B
| $37.3M | 0.06% |
+852,392
| New | +$37.2M |
|
449
Valley National Bancorp
VLY
$8.3B
| $37.2M | 0.06% |
3,194,100
-240,200
| -7% | -$2.57M |
|
450
Public Storage
PSA
$61.4B
| $37.2M | 0.06% |
166,334
-269,400
| -62% | -$57.3M |
|
Similar funds
Jim Simons's Q4 2016 Portfolio in Review
As of Q4 2016, Jim Simons held 3,715 positions worth $63.2B, up 12% from $56.6B the previous quarter. Its ten largest holdings account for 7.2% of the portfolio.
Jim Simons deployed $5.07B of net new capital in Q4 2016, opening 418 new positions and adding to 1,792 existing holdings. Its largest new stake was Broadcom: 10,144,960 shares worth $179M.
By sector, the portfolio is most concentrated in Financials at 14% of assets, up from 12% a quarter earlier, followed by Technology and Healthcare.
On the sell side, the largest reduction was Bristol-Myers Squibb, an estimated $227M trimmed.
- Jim Simons's largest Q4 2016 buy was Broadcom: 10,144,960 shares worth $179M.
- Jim Simons added most to Gilead Sciences in Q4 2016, an estimated $247M increase.
- Jim Simons's biggest Q4 2016 reduction was Bristol-Myers Squibb, cutting an estimated $227M.
- Jim Simons fully exited Alphabet (Google) Class C in Q4 2016, selling an estimated $205M.
- Jim Simons's ten largest holdings make up 7.2% of its $63.2B portfolio in Q4 2016.
- Jim Simons opened 418 new positions and closed 494 in Q4 2016.
- Jim Simons's portfolio value rose 12% quarter-over-quarter to $63.2B.
Based on Renaissance Technologies's 13F filing for Q4 2016, filed 13 Feb 2017.